Immuneering Corporation
IMRX
$5.92
-$0.03-0.50%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -3.70% | -2.72% | -4.07% | 1.74% | 1.06% |
| Depreciation & Amortization | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.96% | 8.76% | 9.69% | 10.19% | 9.15% |
| Operating Income | -5.96% | -8.76% | -9.69% | -10.20% | -9.23% |
| Income Before Tax | -10.81% | -14.03% | -14.15% | -12.46% | -8.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.81% | -14.03% | -14.15% | -12.46% | -8.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.81% | -14.03% | -14.15% | -12.46% | -8.06% |
| EBIT | -5.96% | -8.76% | -9.69% | -10.20% | -9.23% |
| EBITDA | -6.01% | -8.79% | -9.69% | -10.17% | -9.20% |
| EPS Basic | 0.66% | -5.95% | -7.79% | -5.05% | 1.06% |
| Normalized Basic EPS | 1.56% | -4.95% | -6.98% | -3.92% | 0.63% |
| EPS Diluted | 0.66% | -5.95% | -7.79% | -5.05% | 1.06% |
| Normalized Diluted EPS | 1.56% | -4.95% | -6.98% | -3.92% | 0.63% |
| Average Basic Shares Outstanding | 12.63% | 8.17% | 5.54% | 6.66% | 8.96% |
| Average Diluted Shares Outstanding | 12.63% | 8.17% | 5.54% | 6.66% | 8.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |